Table 1.

Significant differences in phosphoprotein changes between tumor types

NSCLC vs. CRC + PDACCRC vs. NSCLC + PDACPDAC vs. NSCLC + CRC
Drug (target)IncreasedNot increasedDecreasedNot decreasedIncreasedNot increasedDecreasedNot decreasedIncreasedNot increasedDecreasedNot decreased
AZD5363 (AKT)RBIR SRCSTAT5IR
Everolimus (m-TOR)SRC S6KMEKRBC-MET IRS1
Gefitinib (EGFR)m-TORIRS1
Luminespib (HSP90)MEKPTENIGF1R IRS1B-CateninC-KIT
Pictilisib (PI3K)m-TOR MEKCHK1 CHK2 PTENGSK3BPRAS40 AKT
Trametinib (MEK)PDGFRB SRCB-Catenin CHK2
Vemurafenib (BRAF)FGFR1 HER3 IR STAT5m-TORCHK1PRAS40 C-KIT
  • NOTE: Changes in phosphorylation of proteins that were increased or decreased upon exposure to different drugs but were significantly different from cells derived from different tumor types, i.e., NSCLC, CRC, and PDAC upon logistic regression corrected for multiple testing.

  • Abbreviation: CRC, colorectal cancer.